RxDoctor Payments Data

Dana Ellis, MD

Dermatology · Lakewood Ranch, FLNPI 1902171341

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $29,159 of the $41,638 with a category attached, or 70.0%. Pfizer accounts for 84.2% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $17,127 and has fallen 58.8% since, to $7,057 in 2025. Among dermatology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,638in general payments, 2019–2025

Across 237 payments — averaging $175.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$35K
  • Dermira, Inc.$2K
  • AbbVie$1K
  • Arcutis Biotherapeutics, Inc.$559
  • Novartis$460
  • UCB, Inc.$399
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$5,92514%
  • Speaking & faculty fees$29,15970%
  • Travel & lodging$6812%
  • Food & beverage$5,79014%
  • Education$830%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,638 in reported general payments places this provider in the 90th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida →

Medicare billing

Part B allowed, 2024
$472,908
Medicare patients
1,391
Services billed
5,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast26$174,102
Dupixent PenDupilumab19$91,443
RinvoqUpadacitinib14$89,520
AdbryTralokinumab-Ldrm15$59,911
Clobetasol Propionate106$4,891
Tacrolimus30$2,816
Fluorouracil31$2,245
Ketoconazole155$1,884
Tretinoin26$1,779
Doxycycline Hyclate92$1,571
Minoxidil143$1,478
Triamcinolone Acetonide114$1,299
Clindamycin Phosphate40$1,132
Fluocinolone Acetonide21$1,057
Metronidazole26$899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$180$174,10226 claims
AbbVieRinvoq$1,021$89,52014 claims
LEO Pharma Inc.Adbry$168$59,91115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,147 dermatology providers in Florida.

Other dermatology in Lakewood Ranch

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →